Menorrhagia Impact Questionnaire: Assessing the influence of heavy menstrual bleeding on quality of life

Current Medical Research and Opinion

Volumn 26, Issue 12, 2010, Pages 2745-2755

  Bushnell, Donald M ^a   Martin, Mona L ^a   Moore, Keith A ^b   Richter, Holly E ^c   Rubin, Arkady ^d   Patrick, Donald L ^e  

^a Health Research Associates Inc   (United States)

^b Xanodyne Pharmaceuticals Inc   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d ARSTAT   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Activity limitation; Heavy menstrual bleeding; Menorrhagia; Patient reported outcome (PRO); Quality of life; Questionnaire

Indexed keywords

LYSTEDA; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENORRHAGIA; MENORRHAGIA IMPACT QUESTIONNAIRE; PSYCHOMETRY; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; SELF REPORT; SENSITIVITY AND SPECIFICITY; TEST RETEST RELIABILITY; VALIDATION PROCESS;

ACTIVITIES OF DAILY LIVING; ADULT; ANTIFIBRINOLYTIC AGENTS; COST OF ILLNESS; FEMALE; HUMANS; MENORRHAGIA; MENSTRUATION; MIDDLE AGED; QUALITY OF LIFE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SICKNESS IMPACT PROFILE; TRANEXAMIC ACID; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78349280268     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.532200     Document Type: Article

References (32)

1. NHS Centre for Reviews and Dissemination. Management of menorrhagia. Effective Health Care 1995;1:1-15
2. Lethaby A, Farquhar C. Treatments for heavy menstrual bleeding. BMJ 2003;327:1243-44
3. Shapley M, Jordan K, Croft, PR. An epidemiological survey of symptoms of menstrual loss in the community. Br J Gen Pract 2004;54:359-63
4. Hickey M, Higham JM, Fraser I. Progestogens versus oestrogens and pro-gestogens for irregular uterine bleeding associated with anovulation. Cochrane Database Syst Rev 2007;4:CD001895
5. Apgar BS, Kaufman AH, George-Nwogu U, et al. Treatment of menorrhagia. Am Fam Physician 2007;75:1813-19
6. Haynes PJ, Hodgson H, Anderson AB, et al. Measurement of menstrual blood loss in patients complaining of menorrhagia. Br J Obstet Gynaecol 1977;84:763-8
7. Warner PE, Critchley HOD, Lumsden HA, et al. Menorrhagia II: is the 80 mL blood loss criterion useful in management of complaint of menorrhagia? Am J Obstet Gynecol 2004;190:1224-9
8. National Collaborating Centre for Women's and Children's Health: Heavy menstrual bleeding. National Institute for Health and Clinical Excellence. London, England 2007 Available at http://www.nice.org.uk/guidance/ CG44/guidance/pdf/English [Last accessed on July 15 2010.
9. Duckitt K, Collins S. BMJ Clinical Evidence. Menorrhagia. BMJ Publishing Group Ltd., London, England, 2006. Available at: http://clinicalevidence.bmj. com/ceweb/conditions/woh/0805/0805.jsp [Last accessed on July 15, 2010]
10. Shankar M, Chi C, Kadir RA. Review of quality of life: menorrhagia in women with or without inherited bleeding disorders. Haemophilia 2008;14:15-20
11. Habiba M, Julian S, Taub N, et al. Limited role of multi-attribute utility scale and SF-36 in predicting management outcome of heavy menstrual bleeding. Eur J Obstet Gynecol Reprod Biol 2010;148:81-5
12. Matteson KA, Clark MA. Questioning our questions: do frequently asked questions adequately cover the aspects of women's lives most affected by abnormal uterine bleeding? Opinions of women with abnormal uterine bleeding participating in focus group discussions. Women Health 2010; 50:195-211
13. Jenkinson C, Peto V, Coulter A. Making sense of ambiguity: evaluation in internal reliability and face validity of the SF 36 questionnaire in women presenting with menorrhagia. Qual Health Care 1996;5:9-12
14. Moos RH. The Development of a Menstrual Distress Questionnaire. Psych Med 1968;30:853-867
15. Ruta DA, Garratt AM, Chadha YC, et al. Assessment of patients with menor-rhagia: how valid is a structured clinical history as a measure of health status? Qual Life Res 1995;4:33-40
16. Shaw RW, Brickley MR, Evans L, et al. Perceptions of women on the impact of menorrhagia on their health using multi-attribute utility assessment. Br J Obstet Gynaecol 1998;105:1155-9
17. Lamping DL, Rowe P, Clarke A, et al. Development and validation of the menorrhagia outcomes questionnaire. Br J Obstet Gynaecol 1998; 105:766-79
18. Shapley M, Jordan K, Croft PR. Abnormal bleeding patterns associated with menorrhagia in women in the community and in women presenting to primary care. Fam Pract 2007;24:532-7
19. Santer M, Wyke S, Warner P. What aspects of periods are most bothersome for women reporting heavy menstrual bleeding? Community survey and qualitative study. BMC Womens Health 2007;7:8
20. Winkler UH. The effect of tranexamic acid on the quality of life of women with heavy menstrual bleeding. Eur J Obstet Gynecol Reprod Biol 2001;99:238-43
21. National Institute for Health and Clinical Excellence. Heavy menstrual bleeding. London, England: NICE Clinical Guideline CG44, 2007. Available at www.nice.org.uk/CG044 [Last accessed on July 15 2010]
22. Lukes AS, Moore KA, Muse KN, et al. Tranexamic acid treatment for heavy menstrual bleeding: a randomized trial. Obstet Gynecol 2010; 116:865-75
23. US Dept. of Health and Human Services. FDA Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, Silver Spring, MD. December 2009. Available at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM193282.pdf [Last accessed on July 15, 2010.
24. Patrick DL, Burke LB, Powers JH, et al. Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health 2007; 10(Suppl 2):S125-37
25. Ware J, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473-83
26. Scientific Advisory Committee of the Medical Outcomes Trust. Assessing health status and quality-of-life instruments: attributes and review criteria. Qual Life Res 2002;11:193-205
27. Guttman L. A basis for analyzing test-retest reliability. Psychometrika 1945; 10:255-82
28. Cohen JJ. Statistical Power Analysis for the Behavioral Sciences, 2nd edn. Hillsdale, NJ: Lawrence Erlbaum, 1988:8
29. Lysteda [package insert]. Newport KY: Xanodyne Pharmaceuticals Inc. 2009
30. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials 1989;10:407-15
31. Guyatt GH, Osoba D, Wu AW, et al. for the Clinical Significance Consensus Meeting Group. Methods to explain the clinical significance of health status measures. Mayo Clin Proc 2002;77:371-83
32. Patrick DL, Gagnon DD, Zagari MJ, et al. for the Epoetin Alfa Study Group. Assessing the clinical significance of health-related quality of life (HrQOL) improvements in anaemic cancer patients receiving epoetin alfa. Eur J Cancer 2003;39:335-45